US EditionPublished • loading... • Updated
Uganda: Novartis' New Antimalarial Ganlum Offers Hope Against Drug Resistance in Africa
GanLum showed over 97% effectiveness in a trial of 1,688 participants and also blocks malaria transmission to mosquitoes, addressing drug resistance in Africa.
Summary by allAfrica
2 Articles
2 Articles
Novartis reveals new drug to fight malaria resistance and transmission
Swiss pharmaceutical giant Novartis has unveiled a next-generation malaria treatment that not only demonstrates a 97% cure rate but also blocks disease transmission, representing a potential breakthrough in combating drug-resistant strains of the deadly parasite.
·Pointe-Noire, Congo
Read Full Article
Uganda: Novartis' New Antimalarial Ganlum Offers Hope Against Drug Resistance in Africa
Novartis (NOVN.S) has announced the successful completion of a pivotal Phase III trial for its new antimalarial drug, ganaplacide/lumetantrine, branded as GanLum, demonstrating effectiveness on par with existing therapies while offering new hope in the fight against rising drug resistance.
·South Africa
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
